25 reports

  • May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
  • Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear.The company’s OTIPRIO is a FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses investigational candidates targeted...

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Company Financials
  • Otonomy, Inc.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostic
  • Therapy
  • Sensorion S.A.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear, Nose, And Throat Medicine
  • Europe
  • World
  • Product Initiative
  • Sensorion S.A.

According to the American Academy of Otolaryngology, the total cost of a cochlear implant, including everything from evaluation to rehabilitation, can be as much as $##, ##.

  • Ear, Nose, And Throat Medicine
  • World
  • Carl Zeiss AG
  • Danaher Corporation
  • Olympus Corporation
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • from baseline to Month 3 in the OTIVIDEX group vs. 40% for placebo.

Following an initial one month lead-in period, eligible subjects were randomized ##:## to a single intratympanic injection of OTIVIDEX or placebo.

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.

ACCORDING TO THE AMERICAN ACADEMY OF OTOLARYNGOLOGY, THE TOTAL COST OF A COCHLEAR IMPLANT, INCLUDING EVERYTHING FROM EVALUATION TO REHABILITATION CAN COST AS MUCH AS $##, ##.

  • Ear, Nose, And Throat Medicine
  • World
  • Medtronic, Inc.
  • Olympus Corporation
  • Smith & Nephew Plc

He is dual board certified in Otolaryngology and Neurotology by the American Board of Otolaryngology.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Product Initiative
  • Auris Medical Holding AG

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Demand
  • Cochlear Limited
  • Sonova Holding AG
  • 5.2.3 BY REGION
  • is enabling people to purchase the technologically

The ENT devices market is poised to reach USD 14,001.3 million by 2020 from USD 10,219.3 million in 2015, growing at a CAGR of 6.5% from 2015 to 2020. This market is categorized on the basis of products, end users, and regions. Major factors contributing to the growth of the global ENT devices market include high prevalence...

  • Ear, Nose, And Throat Medicine
  • North America
  • United States
  • World
  • Market Size
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • Mar 04, 2011: Auris Medical's AM-111 Protects against Hearing Loss from Cochlear Implant Electrode Insertion Trauma
  • May 04, 2015: Auris Medical Holding Provides Update on Clinical Development Plan for AM-111

Patients were randomized to receive AM-## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear, Nose, And Throat Medicine
  • Psychotic Disorder
  • Turkey
  • World
  • Product Initiative
  • 8.4.3 RECENT DEVELOPMENTS

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Cochlear Limited
  • RION Co., Ltd
  • Sonova Holding AG

You can easily book an appointment with one online.

  • Ear, Nose, And Throat Medicine
  • World
  • Forecast
  • Natus Medical Incorporated
  • William Demant
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere Disease

Lustig, MD, Chair, Department of Otolaryngology at Columbia University Medical Center.

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • Mar 04, 2011: Auris Medical's AM-111 Protects Against Hearing Loss From Cochlear Implant Electrode Insertion Trauma
  • Jan 04, 2018: Auris Medical Provides Update on AM-111 Development Program

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## E.

  • Cancer
  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • World
  • Bristol-Myers Squibb Company
  • Apr 20, 2012
  • FEATURED NEWS & PRESS RELEASES

KG ## ## ## ## ## ## Orbis Biosciences, Inc. ## ## ## ## ## ## Otologic Pharmaceutics, Inc. ## ## ## ## ## ## Xigen SA ## ## ## ## ## ## Total ## ## ## ## ## ## Source: Global Markets Direct Company Name Phase III Phase II Phase I

  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Company Operations
  • Product Initiative

Sikora, M. D., Associate Professor of Otolaryngology and Co-Director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Ear, Nose, And Throat Medicine
  • Sexually Transmitted Disease
  • Vaccine
  • United States
  • Advaxis, Inc.
  • 4.1 BIBLIOGRAPHY

ET AL. (2011) ' HEAD AND NECK CANCER-PART ##: EPIDEMIOLOGY, PRESENTATION, AND PRESERVATION', CLINICAL OTOLARYNGOLOGY, ##(##), PP. ##-##.

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Japan
  • United States
  • Forecast
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Oncology
  • United States
  • World
  • 9.2 References

American Academy of Otolaryngology.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • Therapy
  • World
  • Clinical Trial Profile Snapshots

Sikora, M. D., Associate Professor of Otolaryngology and co-director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Clinical Trial
  • Drug Discovery And Development
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative

Head and neck cancer

4546 5000 3864
  • Epidemiologist Insight

Otolaryngology - Head and Neck Surgery, ##(##), ##-## < DOI> ##. ##/ j. otohns. 2006. ##. ##< / DOI>. de Souza DLB, Bernal Pérez MM, Curado MP (2011) Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal cancer in Spain and implications for cance

  • Ear, Nose, And Throat Medicine
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.

The prominent features of this report are - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative
  • Sensorion S.A.
  • is a representative pipeline of the nanoparticles under review in research
  • NANOPARTICLES FOR INNER EAR DISEASES: RESEARCH PIPELINE AT UNIVERSITIES

INTRODUCTION A significant proportion of the world’s population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing...

  • Ear, Nose, And Throat Medicine
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited